SCHEMBL771713

SCHEMBL771713

CN(C(=O)CCCS(=O)(=O)N1CCCC2CCCC=C21)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 14/20 0.39
PDE3A Q14432 14/20 0.39
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
PDE5A O76074 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
PTAFR P25105 1/20 0.37
CYP2C19 P33261 1/20 0.37
BLM P54132 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PMP22 Q01453 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE1C Q14123 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PDE4A P27815 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770852 0.81 FFAR4 (0.33) ALDH1A1
SCHEMBL770781 0.80 PDE3B (0.39) PDE3BPDE3AKMT2APDE4APDE4B
SCHEMBL770150 0.79 POLB (0.40) MEN1ALDH1A1HPGDTSHRKMT2A
SCHEMBL771792 0.79 ALDH1A1 (0.35) MEN1ALDH1A1TSHRKMT2AHSD17B10
SCHEMBL771132 0.79 POLB (0.40) MEN1ALDH1A1HPGDTSHRKMT2A
SCHEMBL770148 0.79 POLB (0.40) MEN1ALDH1A1HPGDTSHRKMT2A
SCHEMBL770874 0.77 NPC1 (0.47) MEN1ALDH1A1HPGDKMT2A
SCHEMBL770324 0.76 HTT (0.32) KDM4EALDH1A1CYP1A2CYP2C19KMT2A
SCHEMBL770783 0.76 PDE3B (0.38) PDE3BPDE3AMEN1HPGDKMT2A
SCHEMBL770641 0.75 CHRM2 (0.35) MEN1ALDH1A1HPGDKMT2AF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PDE3B 367/4885PDE3A 464/4885KDM4E 4105/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PDE3B 365/4885PDE3A 466/4885KDM4E 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.